Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation.

"Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Wilson acknowledges funding from the 10.13039/100000002National Institutes of HealthR01DK113191 and P30DK079310. Dr. Schulz was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to HugoHealth, a personal health information platform; is cofounder of Refactor Health, an artificial intelligence–augmented data mapping platform for health care; and is a consultant for Interpace Diagnostics Group, a molecular diagnostics company."

"Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org ). Dr. Wilson acknowledges funding from the 10.13039/100000002National Institutes of Health R01DK113191 and P30DK079310. Dr. Schulz was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to HugoHealth, a personal health information platform; is cofounder of Refactor Health, an artificial intelligence–augmented data mapping platform for health care; and is a consultant for Interpace Diagnostics Group, a molecular diagnostics company."